Hybrid fragment synthesis splits long sequences such as GLP-1 agonists into shorter fragments, builds each by solid-phase chemistry, and joins them in solution. This article explains the mechanism, examines the yield, purity, cost, and process mass intensity claims behind it, and separates what is…
Solid-phase peptide synthesis SPPS couples amino acids one at a time onto an insoluble resin. For short peptides the method is dependable and economical, which is why it dominates peptide manufacturing. The problem emerges as chains grow. For sequences in the range of roughly 39 amino acids, the length of GLP-1 agonist peptides, linear SPPS becomes difficult to run at practical cost and quality.
The mechanism is physical. As a peptide chain elongates on the resin, it begins to fold. The folded chain blocks access to the reactive amine at the growing terminus, so each successive coupling becomes slower and less complete. Couplings that do not go to completion leave behind deletion sequences and truncated chains. By the end of a long linear synthesis, the crude product carries a complex impurity profile that includes missing amino acids and prematurely terminated sequences. That profile lowers overall yield and complicates purification, because the impurities are close enough in charge and hydrophobicity to the target product that chromatographic separation is slow and expensive.
AmbioPharm, a peptide contract development and manufacturing organization CDMO , describes this as the central manufacturing problem for GLP-1 agonists. Its chief executive, Brian Gregg, a peptide CDMO veteran whose early work included exenatide, states that linear synthesis makes long drug candidates impractical or uneconomic to produce at scale. The claim is consistent with how the industry has behaved: most peptide CDMOs invested heavily in linear SPPS over the decade and a half that the broader industry grew up around it, and that installed base tends to steer customers toward the same approach.
Hybrid fragment synthesis takes a different path. The target sequence is divided into three to five shorter fragments. Each fragment is synthesized independently by SPPS, and the fragments are then joined in solution by liquid-phase peptide synthesis LPPS . AmbioPharm describes this as its standard production route for long peptides.
The advantages follow from the chemistry. Because each fragment is much shorter than the full sequence, the folding problem that degrades long linear couplings is largely avoided. Each fragment is built with high coupling efficiency and carries a simpler impurity set. The subsequent solution-phase joining adds its own chemistry, but the starting materials are cleaner, so the final crude peptide is cleaner as well. AmbioPharm reports that hybrid synthesis yields a crude product with simpler impurities, easier purification, and higher yield than a comparable linear run, along with lower long-term cost, shorter lead times, and reduced manufacturing risk. These are company claims. No comparative process data, chromatograms, or yield tables were released with them.
The timeline advantage is structural rather than chemical. A linear synthesis builds the chain in one pass, so the number of coupling cycles is fixed by the sequence length. Fragment synthesis runs the fragments in parallel. Three to five shorter syntheses can be completed at the same time, and only the final joining steps are sequential. That parallelization compresses the overall production campaign, a meaningful factor when a customer needs large volumes on a deadline.
There is precedent for the approach at industrial scale. Eli Lilly's publicized success with hybrid fragment manufacturing for its GLP-1 portfolio, as reported publicly, raised industry awareness and increased demand for CDMOs that can actually run hybrid processes. The technical details of Lilly's route were not disclosed in the source describing AmbioPharm's position, so the public record supports the general point that hybrid chemistry can be scaled, not the specific claim that any particular vendor's process matches it.
The environmental argument for hybrid synthesis rests on process mass intensity PMI . PMI is calculated as the total mass of raw materials, including solvents, reagents, and amino acid derivatives, divided by the mass of final API product. Lower PMI means less input material and less waste per unit of product.
For a 39-mer GLP-1 peptide made by linear SPPS, the figure typically cited is 20,000 to 30,000. That means 20 to 30 metric tons of input mass for every kilogram of API, a ratio driven by the enormous solvent volumes and repeated wash cycles inherent to solid-phase chemistry. AmbioPharm claims its hybrid approach delivers a three- to fourfold reduction in process mass intensity versus linear SPPS for the same molecule.
Note what is and is not being claimed. The company has not disclosed an absolute PMI value for its hybrid process, only a relative reduction factor. A three- to fourfold reduction from a baseline of 20,000 to 30,000 would put hybrid PMI in the range of 5,000 to 10,000, still high in absolute terms, but no commercial figure has been published. The comparison is vendor-reported and has not been independently reproduced.
The customer pull behind PMI is real even when the numbers are thin. Large pharmaceutical companies with public environmental and ESG commitments have begun asking CDMOs for waste metrics during vendor selection. AmbioPharm's executives state that sustainability capability in hybrid manufacturing is moving from a market differentiator to a baseline expectation for preferred partners. That is a market observation, plausible but not quantified anywhere in the source.
The GLP-1 story helps calibrate how much of the hybrid argument is real. Exenatide, the first GLP-1 receptor agonist to reach the market, is a 39-amino-acid peptide. It was originally discovered in Gila monster venom and was manufactured by solid-phase synthesis at commercial scale, which is precisely the regime where the hybrid argument says linear SPPS becomes painful.
Peptide Atlas's own dataset illustrates how thin the public research record can be for an established drug. The exenatide entry lists 0 registered clinical trials on file and 1 indexed PubMed paper: the EXSCEL cardiovascular outcomes trial, published in the New England Journal of Medicine on 2017-09-14 PMID 28910237 . The gap between that sparse index record and the drug's real commercial history is itself a reminder that manufacturing know-how for peptide drugs sits largely inside CDMOs and sponsors, not in the published literature.
Brian Gregg's career connects to that history. His early work on exenatide predates the current GLP-1 boom, and the arc from exenatide to the present day illustrates the scale change. GLP-1 development has evolved from single agonists to dual and triple agonists, molecules that are longer and more complex than first-generation compounds. The commercial success of the class has shifted the industry's risk tolerance for peptide drugs, and peptide development is expanding beyond metabolic disease into oncology, endocrinology, autoimmune disease, and arthritis. Every one of those programs eventually faces the same question: can the molecule be manufactured at the volumes and cost a global market requires?
That is the strategic stake in the hybrid argument. If a manufacturing route can deliver larger volumes faster at lower cost of goods, previously deprioritized peptide programs become commercially viable. The claim is commercially sensible. It is also, in the source material, an executive assessment with no cost data attached.
The manufacturing argument is being built out in physical form. AmbioPharm completed a major expansion of its Shanghai facility with full SPPS, LPPS, and hybrid synthesis capabilities, replacing an aging site to meet near-term demand. The company is now replicating that facility design in South Carolina, with 68,000 square feet of added space and synthesis capabilities targeted to be fully operational by Q4 2027.
The twin-facility design is the operational payload of the hybrid strategy. Two identical facilities allow technical transfer between sites without redeveloping processes, reduce supply chain risk, and let customers serve US, European, and Chinese markets from either site. Shanghai was built first for practical reasons: an existing building was already earmarked, construction costs were lower, and construction in China was faster than a greenfield US build would have been.
The US construction is being accelerated with prefabricated modular methods. Modules built in China, with engineering collaboration from Shanghai, are shipped to South Carolina and assembled on site. AmbioPharm targets a two-year project timeline for the modular build, versus three or more years for a conventional stick-built facility. The two-year figure is a target, not a verified completion status.
The utilization assumptions behind the US build are substantial. The investment was based on customer growth forecasts, and AmbioPharm expects the new US capacity to reach full utilization within three to four years of coming online, with further expansion expected within the following five years. Those projections rest on customer forecasts, not on committed orders disclosed in the source.
The dual-geography model also reflects a shifting industry map. Some estimates put China at roughly 20 to 30 percent of global drug development, second to the United States at about 40 percent, with China's share increasing. A CDMO with capabilities in both countries can help Chinese drug innovators license products to US and European companies by enabling rapid technology transfer and clinical development outside China. Established global pharma customers, in turn, can use both sites as supply nodes for different markets, including the growing Chinese market. These are strategic claims from the company, and the source gives the China share estimate no verifiable origin.
Taken as a whole, the case for hybrid fragment synthesis rests on a sound chemical premise and a thin public evidence base. The premise, that long linear SPPS chains suffer folding-related coupling failures and accumulating truncation impurities, is well established in peptide chemistry. The corollary, that shortening the chains by fragmenting the sequence reduces that failure mode, is mechanistically reasonable. The quantitative claims attached to it, higher yield, easier purification, lower cost, shorter timelines, and a three- to fourfold PMI reduction, are vendor-reported and have not been independently verified. No absolute PMI values for the hybrid process have been disclosed. No yield tables, cost comparisons, or named drug programs have been published.
The source material is an executive narrative from the company's own podcast, so the benefits are claimed by the party selling the service. That does not make them wrong, but it should govern how a buyer reads them. Utilization and expansion projections are based on customer forecasts, not commitments. The two-year modular construction timeline is a target. The China drug development share is attributed to "some estimates" without a named source.
There are also technical questions the public discussion does not address. Liquid-phase fragment joining carries its own risks: fragment solubility in the coupling solvent, racemization at the joining site, and the purity of the fragments themselves. If a fragment carries an impurity into the joining step, that impurity can propagate into the final product. The current claims do not say how much of the hybrid advantage comes from parallel synthesis versus improved yield and easier purification, which matters for scheduling and cost modeling. And it is not established whether hybrid routes are practical for non-linear peptide formats such as cyclic, stapled, or heavily modified peptides, an increasingly important part of the pipeline.
For a researcher or procurement team evaluating manufacturing routes for a long peptide, the hybrid option deserves a formal comparison, not an assumption. The practical checklist is straightforward.
Benchmark process mass intensity. Ask any CDMO for the PMI of its proposed route, linear or hybrid, and compare like for like. The 20,000 to 30,000 figure for a linear 39-mer is a useful reference point, but the absolute value depends on the specific sequence, resin, and purification strategy.
Ask about demonstrated scale. Hybrid synthesis in a laboratory is one thing; hybrid synthesis at commercial scale is another. A credible vendor should be able to show pilot-to-commercial campaigns, not just process descriptions. Ask which molecules have been run through the route and what the joining yields were.
Ask how fragment boundaries were chosen. The number of fragments, three to five in the typical design, and the location of the cuts determine the solubility and racemization risk at each joining step. A vendor should be able to explain the selection logic for the specific molecule under consideration.
Ask about site transfer. If a CDMO offers mirror facilities in different geographies, confirm that the process was actually transferred between them and that the quality systems are aligned. Mirror facility design is a supply chain argument, and its value depends on execution.
Ask about regulatory status. For a commercial product, the manufacturing route is locked in by regulatory filings. Confirm which facilities, and which versions of the process, are covered by the relevant submissions.
The unresolved questions matter for anyone planning around hybrid synthesis. What absolute PMI values does the process achieve in commercial production? At what peptide length does hybrid clearly outperform linear SPPS in cost and purity? Do the claimed advantages hold across peptide classes and production scales? These are answerable questions, but the answers currently sit inside CDMO process data rather than in the public record. For now, the chemistry is credible, the claims are directional, and the obligation is on the buyer to ask for the numbers.
Peptides referenced: Exenatide, GLP-1.
Related reading: PEC Purification for GLP-1 Manufacturing: Liraglutide Case Study, WorkBeads SEC Resins: Porosity, Selectivity and Operating Conditions, Balancing Chemistry and Timelines in Complex Peptide Synthesis, Therapeutic Peptides: Classes, Applications and Synthesis Challenges.